JP2023510351A5 - - Google Patents

Info

Publication number
JP2023510351A5
JP2023510351A5 JP2022542337A JP2022542337A JP2023510351A5 JP 2023510351 A5 JP2023510351 A5 JP 2023510351A5 JP 2022542337 A JP2022542337 A JP 2022542337A JP 2022542337 A JP2022542337 A JP 2022542337A JP 2023510351 A5 JP2023510351 A5 JP 2023510351A5
Authority
JP
Japan
Prior art keywords
cdr
seq
complex according
complex
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542337A
Other languages
English (en)
Japanese (ja)
Other versions
JP7866502B2 (ja
JP2023510351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012764 external-priority patent/WO2021142313A1/en
Publication of JP2023510351A publication Critical patent/JP2023510351A/ja
Publication of JP2023510351A5 publication Critical patent/JP2023510351A5/ja
Application granted granted Critical
Publication of JP7866502B2 publication Critical patent/JP7866502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542337A 2020-01-10 2021-01-08 筋標的化複合体およびそれらの使用 Active JP7866502B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062959804P 2020-01-10 2020-01-10
US62/959,804 2020-01-10
US202062965754P 2020-01-24 2020-01-24
US62/965,754 2020-01-24
US202062968411P 2020-01-31 2020-01-31
US62/968,411 2020-01-31
US202062980925P 2020-02-24 2020-02-24
US62/980,925 2020-02-24
US202063055521P 2020-07-23 2020-07-23
US63/055,521 2020-07-23
US202063061836P 2020-08-06 2020-08-06
US63/061,836 2020-08-06
US202063069067P 2020-08-23 2020-08-23
US63/069,067 2020-08-23
US202063132929P 2020-12-31 2020-12-31
US63/132,929 2020-12-31
PCT/US2021/012764 WO2021142313A1 (en) 2020-01-10 2021-01-08 Muscle-targeting complexes and uses thereof

Publications (3)

Publication Number Publication Date
JP2023510351A JP2023510351A (ja) 2023-03-13
JP2023510351A5 true JP2023510351A5 (cg-RX-API-DMAC7.html) 2024-01-17
JP7866502B2 JP7866502B2 (ja) 2026-05-27

Family

ID=76788871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542337A Active JP7866502B2 (ja) 2020-01-10 2021-01-08 筋標的化複合体およびそれらの使用

Country Status (6)

Country Link
US (1) US20230226212A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087876A4 (cg-RX-API-DMAC7.html)
JP (1) JP7866502B2 (cg-RX-API-DMAC7.html)
CN (1) CN115427448A (cg-RX-API-DMAC7.html)
CA (1) CA3163608A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021142313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3222816A1 (en) * 2021-06-21 2022-12-29 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
JPWO2022270585A1 (cg-RX-API-DMAC7.html) 2021-06-23 2022-12-29
CA3226301A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US20240318176A1 (en) * 2021-07-09 2024-09-26 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525613A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
WO2023026994A1 (ja) * 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
EP4396351A4 (en) * 2021-09-01 2025-12-24 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
US11833221B2 (en) * 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2025522433A (ja) 2022-06-15 2025-07-15 アローヘッド ファーマシューティカルズ インコーポレイテッド スーパーオキシドジスムターゼ1(SOD1)の発現を阻害するためのRNAi剤、その組成物、及び使用の方法
WO2025072886A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025076006A2 (en) * 2023-10-02 2025-04-10 Avidity Biosciences, Inc. Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping
WO2025085810A2 (en) * 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
EP4652282A4 (en) * 2023-11-14 2026-06-24 Cavalry Biosciences Inc Compositions designed to target muscle cells and their uses
US12527877B2 (en) 2024-01-24 2026-01-20 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
CN118531138B (zh) * 2024-06-18 2025-04-01 湖北省农业科学院畜牧兽医研究所 猪肉品质和胴体关联的snp及应用
WO2025262186A2 (en) * 2024-06-20 2025-12-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic oligonucleotides for treating diseases being associated with or caused by a missense, nonsense or in-frame indel mutation
CN118516348B (zh) * 2024-07-23 2025-01-17 深川生物科技(山东)股份公司 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用
WO2026163078A1 (en) * 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
KR20240172236A (ko) * 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
WO2018136626A1 (en) * 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法

Similar Documents

Publication Publication Date Title
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP2023509793A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP7803926B2 (ja) ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
JP7829488B2 (ja) 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
JP2021533199A5 (cg-RX-API-DMAC7.html)
JP2023535078A5 (cg-RX-API-DMAC7.html)
US11771776B2 (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2021533200A5 (cg-RX-API-DMAC7.html)
JP2021532832A5 (cg-RX-API-DMAC7.html)
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP2023535444A5 (cg-RX-API-DMAC7.html)
JP2021533197A5 (cg-RX-API-DMAC7.html)
JP2023535074A5 (cg-RX-API-DMAC7.html)
IL294478A (en) Muscle targeting complexes and their uses for the treatment of dystrophinopathy
IL294480A (en) Muscle-oriented complexes and their uses for the treatment of atrophy of the muscles of the face, shoulder blades, and arms
JP2024525614A5 (cg-RX-API-DMAC7.html)
CA3226301A1 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533198A5 (cg-RX-API-DMAC7.html)
CA3226307A1 (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20230042713A (ko) 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도
JP2024527362A5 (cg-RX-API-DMAC7.html)
IL319265A (en) Anti-transferrin receptor antibodies and their uses